JP2015523404A - Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 - Google Patents
Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 Download PDFInfo
- Publication number
- JP2015523404A JP2015523404A JP2015524747A JP2015524747A JP2015523404A JP 2015523404 A JP2015523404 A JP 2015523404A JP 2015524747 A JP2015524747 A JP 2015524747A JP 2015524747 A JP2015524747 A JP 2015524747A JP 2015523404 A JP2015523404 A JP 2015523404A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- phenyl
- carboxylic acid
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1ccccc1 Chemical compound *c1ccccc1 0.000 description 4
- PULOLFIJJRREEK-MNOVXSKESA-N CC(C)(C)OC(N(C1CC1)[C@@H](CCNC1)[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(C1CC1)[C@@H](CCNC1)[C@@H]1F)=O PULOLFIJJRREEK-MNOVXSKESA-N 0.000 description 1
- QOPCKHORMCIKGH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(cc1)cnc1-c(cc1)ccc1S(C)(=O)=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(cc1)cnc1-c(cc1)ccc1S(C)(=O)=O)=O)=O QOPCKHORMCIKGH-UHFFFAOYSA-N 0.000 description 1
- ZJDCUFUKRGDEKZ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(cc1)cnc1Br)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(cc1)cnc1Br)=O)=O ZJDCUFUKRGDEKZ-UHFFFAOYSA-N 0.000 description 1
- LSRNVLUFBNHTKJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)c[n]1-c(cc1)ccc1S(C)(=O)=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)c[n]1-c(cc1)ccc1S(C)(=O)=O)=O)=O LSRNVLUFBNHTKJ-UHFFFAOYSA-N 0.000 description 1
- ILNYRJZBDKVIKG-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)ncc1-c1cnc[o]1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)ncc1-c1cnc[o]1)=O)=O ILNYRJZBDKVIKG-UHFFFAOYSA-N 0.000 description 1
- YKZCAUBWOHJNQD-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)ncc1Br)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c(nc1)ncc1Br)=O)=O YKZCAUBWOHJNQD-UHFFFAOYSA-N 0.000 description 1
- BOZDPCKXUFFGAW-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[nH]cn1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[nH]cn1)=O)=O BOZDPCKXUFFGAW-UHFFFAOYSA-N 0.000 description 1
- INZYHFVULOXIMS-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[o]c(-c(cc2)cc(F)c2C#N)n1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[o]c(-c(cc2)cc(F)c2C#N)n1)=O)=O INZYHFVULOXIMS-UHFFFAOYSA-N 0.000 description 1
- KAZDUHROMDBBFA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[s]c(-c(cc2)ccc2C#N)n1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1c[s]c(-c(cc2)ccc2C#N)n1)=O)=O KAZDUHROMDBBFA-UHFFFAOYSA-N 0.000 description 1
- NOMZMZUHBZIXLV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1cnc(-c2cnc[o]2)[o]1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1cnc(-c2cnc[o]2)[o]1)=O)=O NOMZMZUHBZIXLV-UHFFFAOYSA-N 0.000 description 1
- UFDAIOABMJKFOT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1n[o]c(-c(ccc(C#N)c2)c2F)c1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1n[o]c(-c(ccc(C#N)c2)c2F)c1)=O)=O UFDAIOABMJKFOT-UHFFFAOYSA-N 0.000 description 1
- GFTSPSIAVKQJDI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1ncc(-c(cc2)ccc2C#N)[o]1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(C1CC1)C(c1ncc(-c(cc2)ccc2C#N)[o]1)=O)=O GFTSPSIAVKQJDI-UHFFFAOYSA-N 0.000 description 1
- HQPIILKGTFWSDJ-UHFFFAOYSA-N CC(C=C1)=CN(C)C1=O Chemical compound CC(C=C1)=CN(C)C1=O HQPIILKGTFWSDJ-UHFFFAOYSA-N 0.000 description 1
- SEBBVBXEJFSJAU-UHFFFAOYSA-N CCNC(c(cc1)ccc1-c1nc(C(N(C2CC2)C(CC2)CCN2C(OC(C)(C)C)=O)=O)c[o]1)=O Chemical compound CCNC(c(cc1)ccc1-c1nc(C(N(C2CC2)C(CC2)CCN2C(OC(C)(C)C)=O)=O)c[o]1)=O SEBBVBXEJFSJAU-UHFFFAOYSA-N 0.000 description 1
- XEJUFMRKBZMOLA-UHFFFAOYSA-N CCOC(c1n[o]c(-c(cc2)cc(F)c2S(C)(=O)=O)n1)=O Chemical compound CCOC(c1n[o]c(-c(cc2)cc(F)c2S(C)(=O)=O)n1)=O XEJUFMRKBZMOLA-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- XILPCSMEKCBYFO-UHFFFAOYSA-N C[n]1cnnc1 Chemical compound C[n]1cnnc1 XILPCSMEKCBYFO-UHFFFAOYSA-N 0.000 description 1
- DJWYQXAKJWJBOT-UHFFFAOYSA-N Cc1c(-c(cc2)ncc2C(OC)=O)[o]cn1 Chemical compound Cc1c(-c(cc2)ncc2C(OC)=O)[o]cn1 DJWYQXAKJWJBOT-UHFFFAOYSA-N 0.000 description 1
- KCBVSQSTSNISTA-UHFFFAOYSA-N Cc1c(C(O)=O)[s]c(-c(ccc(C#N)c2)c2F)n1 Chemical compound Cc1c(C(O)=O)[s]c(-c(ccc(C#N)c2)c2F)n1 KCBVSQSTSNISTA-UHFFFAOYSA-N 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- VHWFNFITHSPBSR-UHFFFAOYSA-N Cc1c[o]nc1 Chemical compound Cc1c[o]nc1 VHWFNFITHSPBSR-UHFFFAOYSA-N 0.000 description 1
- TWGNOYAGHYUFFR-UHFFFAOYSA-N Cc1cncnc1 Chemical compound Cc1cncnc1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 description 1
- LMMOVHCTLKMZLU-VZUCSPMQSA-N N#Cc1ccc(/C=N/O)cc1F Chemical compound N#Cc1ccc(/C=N/O)cc1F LMMOVHCTLKMZLU-VZUCSPMQSA-N 0.000 description 1
- DFRIYTYFYZKLJD-UHFFFAOYSA-N N=C(C(O)=O)/N=C\Nc(cc1)ccc1C#N Chemical compound N=C(C(O)=O)/N=C\Nc(cc1)ccc1C#N DFRIYTYFYZKLJD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179028.1 | 2012-08-02 | ||
| EP12179028 | 2012-08-02 | ||
| PCT/EP2013/065862 WO2014019967A1 (en) | 2012-08-02 | 2013-07-29 | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015523404A true JP2015523404A (ja) | 2015-08-13 |
| JP2015523404A5 JP2015523404A5 (enExample) | 2017-08-31 |
Family
ID=48875067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524747A Pending JP2015523404A (ja) | 2012-08-02 | 2013-07-29 | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20140045823A1 (enExample) |
| EP (1) | EP2880027B1 (enExample) |
| JP (1) | JP2015523404A (enExample) |
| WO (1) | WO2014019967A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2607889T3 (es) * | 2012-09-25 | 2017-04-04 | Bayer Cropscience Ag | 3-fenilisoxazolin-5-carboxamidas 5-oxi-sustituidas y 3-fenilisoxazolin-5-tioamidas 5-oxi-sustituidas con actividad herbicida y fungicida |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| BRPI0710839A2 (pt) * | 2006-04-06 | 2011-08-23 | Prosidion Ltd | agonistas heterocìclicos de gpcr |
| DE602007008237D1 (de) * | 2006-06-08 | 2010-09-16 | Amgen Inc | Benzamidderivate und assoziierte verwendungen |
| CA2774573A1 (en) * | 2009-10-09 | 2011-04-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| EP2686312B1 (en) * | 2011-03-14 | 2016-08-31 | Boehringer Ingelheim International GmbH | N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators |
| WO2012168315A1 (en) * | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
| FR2992637B1 (fr) * | 2012-06-29 | 2014-07-04 | IFP Energies Nouvelles | Photocatalyseur composite a base de sulfures metalliques pour la production d'hydrogene |
-
2013
- 2013-07-29 EP EP13741779.6A patent/EP2880027B1/en active Active
- 2013-07-29 JP JP2015524747A patent/JP2015523404A/ja active Pending
- 2013-07-29 WO PCT/EP2013/065862 patent/WO2014019967A1/en not_active Ceased
- 2013-07-31 US US13/955,170 patent/US20140045823A1/en not_active Abandoned
-
2016
- 2016-02-16 US US15/044,719 patent/US9926308B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106561A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| WO2009117421A2 (en) * | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2880027B1 (en) | 2016-09-28 |
| US9926308B2 (en) | 2018-03-27 |
| US20160159784A1 (en) | 2016-06-09 |
| US20140045823A1 (en) | 2014-02-13 |
| EP2880027A1 (en) | 2015-06-10 |
| WO2014019967A1 (en) | 2014-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5935154B2 (ja) | Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド | |
| JP6094578B2 (ja) | 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン | |
| JP6011543B2 (ja) | 糖尿病、肥満および関連疾患の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP5703393B2 (ja) | 糖尿病、肥満および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての縮合ジヒドロフラン | |
| JP2018526405A (ja) | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 | |
| TW201348239A (zh) | 環狀橋頭醚ｄｇａｔ１抑制劑 | |
| JP6883045B2 (ja) | オレキシン受容体調節因子としてのハロ置換ピペリジン | |
| JP6066126B2 (ja) | 新規化合物、医薬組成物及びその使用 | |
| JP6136032B2 (ja) | 新規な２，３−ジヒドロ−フロ［２，３−ｃ］ピリジン、Ｇタンパク質共役受容体ＧＰＲ１１９のモジュレーターとしてのそれらの使用、及びそれらを含む医薬組成物 | |
| JP6263789B2 (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP2015523404A (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド、これらを含有する医薬組成物およびその使用 | |
| JP6212827B2 (ja) | Ｎ−シクロプロピル−ｎ−ピペリジニル−アミド誘導体、およびｇｐｒ１１９モジュレーターとしてのそれらの使用 | |
| JP6119081B2 (ja) | Ｇｐｒ１１９に対するフロ［２，３−ｃ］ピリジン活性物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160728 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160728 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170413 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170718 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170828 |